Subanalyses including superficially spreading and nodular melanomas only showed a significant correlation of cytoplasmic MSX2 positivity with both recurrence-free (P=0.015; Figure 6B) and overall survival (P=0.024; Figure 6D). Here, MSX2 is linked to nodular malignant melanoma.